Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Pacira Pharma (PCRX) Misses Q4 EPS by 5c, Sales Beat
February 25, 2016 7:34 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.22, $0.05 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $68.4 million.
We finished 2015 with a solid performance in spite of the challenges we faced this past... More



